Zusammenfassung
Hahn entdeckte 1943 zufällig, daß bei Hunden eine alimentäre Lipämie nach intravenöser Injektion von Heparin innerhalb weniger Minuten verschwindet. Das durch die Lipämie getrübte Plasma wird klar. Diese Klärung alimentär lipämischen Plasmas gelingt nicht, wenn man Heparin in vitro zusetzt. Mit „Post-heparinplasma“, also Plasma, das nach einer vorausgegangenen Heparininjektion entnommen wurde, läßt sich dagegen auch in vitro eine Klärung von lipämischem Plasma erreichen (Anderson und Fawcett 1950). Durch die Heparininjektion muß demnach im Blut ein „Klärfaktor“ aufgetreten sein, der vorher nicht da war. Lindgren, Freeman und Graham (1952) beobachteten am Boden von Ultra-zentrifugenröhrchen mit Plasma, in dem eine Klärung abgelaufen war, einen Niederschlag von Calciumseifen. Dies war der erste Hinweis darauf, daß während der Klärung möglicherweise Triglyceride gespalten werden. Bald wurde dann eine Freisetzung von Fettsäuren durch Titration direkt nachgewiesen (Nichols, Freeman, Shore und Rubin 1952) und man erkannte, daß die Wirkung des Klärfaktors in der fermentativen Spaltung der in den Lipoproteiden des Plasmas enthaltenen Triglyceride zu freien Fettsäuren und Glycerin besteht (Shore, Nichols und Freeman 1953). Die Zunahme der freien Fettsäuren im Gemisch von Post-heparinplasma und lipämischem Plasma geht der Klärung, gemessen als Abfall der optischen Dichte des Plasmas, und der Abnahme der Triglyceride parallel (Grossman, Stadler, Cushing und Palm 1955).
Aus der Medizinischen Klinik des Städtischen Krankenhauses Stuttgart-Bad Cannstatt (Direktor Prof. Dr. G. Schettler)
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Aladjem, F., and L. Rubin: Serum lipoprotein changes during fasting in rabbits. Amer. J.Physiol. 178, 267–268 (1954).
Albrink, M. J., E. B. Man and J. P. Peters: The relation of neutral fat to lactescence of serum. J. clin. Invest. 34, 147–157 (1955).
Albrink, M. J., E. B. Man and J. P. Peters: The relation of neutral fat to lactescence of serum. J. clin. Invest. 34, 147–157 (1955).
Albrink, M. J., J. R. Fitzgerald and E. B. Man: Effect of glucagon on alimentary lipemia. Proc. Soc. exp. Biol. (N. Y.) 95, 778–780 (1957).
Albrink, M. J., J. R. Fitzgerald and E. B. Man: Reduction of alimentary lipaemia by glucose. Metabolism 7, 162–171 (1958).
Anderson, N. G., and B. Fawcett: An antichylomicronemic substance produced by heparin Injection. Proc. Soc. Exp. Biol. (N. Y.) 74, 768–771 (1950).
Anfinsen, C. B., E. Boyle and R. K. Brown: The rôle of heparin in lipoprotein metabolism. Science 115, 583–586 (1952).
Anfinsen, C. B., and T. W. Quigley: Purification of clearing factor by substrate–complex formation. Circulation 8, 435–436 (1953).
Anfinsen, C. B., and T. W. Quigley: On The Role of Lipemia Clearing Factor In Lipid Transport. In: V. A. Najjar: Fat metabolism (a symposium), pp. 93–110 Baltimore: John Hopkins Press 1954.
Angervall, G., and B. Hood: Studies on heparin and lipemia clearing factor, inhibition towards clearing in plasma from normal and atherosclerotic individuals. Acta med. scand. 157, 407–415 (1957).
Antonini, F. M., and L. Salvini: Mucopolysaccharides, clearing factor, age and athero-sclerosis. Bull. Schweiz. Akad. med. Wiss. 13, 209–228 (1957).
Appel, W., U. K. J. Hansen: Über den Abfall der veresterten Fettsäuren und der Amino-säuren des Blutes nach Insulin. Hoppe-Seylers Z. physiol. Chem. 297, 49–60 (1954).
Appel, W., U. H. Ketjer: Über den Abfall der veresterten Fettsäuren nach Insulin. Hoppe-Seylers Z. physiol. Chem. 808, 251–256 (1957).
Avigan, J., R. Redfield and D. Steinberg: N-terminal residues of serum lipoproteins. Biochim. biophys. Acta 20, 557–558 (1956).
Baker, P. S.: Heparin-activated clearing factor (standardized test, agewise application, and clinical observations). Circulation 15, 889–896 (1957).
Baker, P. S., P. P. Foi, P. B. Szanto and A. Dubin: Lipoprotein lipase and serum lipids in experimental biliary obstruction. Circulation 20, 977 (1959).
Ballou, G. A., P. D. Boyer and J. M. Ltjck: The electrophoretic mobility of human serum albumin as affected by lower fatty acid salts. J. biol. Chem. 159, 111–116 (1945).
Balo, J., U. I. Banga: a) Die Zerstörung der elastischen Fasern der Gefäßwand. Schweiz. Z. Path. 12, 350–362 (1949); b) Elastase and elastase inhibitor. Nature (Lond.) 164, 491 (1949).
Balo, J., U. I. Banga: Elastolytic activity of pancreatic extracts. Biochem. J. 46, 384–387 (1950).
Becker, G. H., J. Meyer and H. Necheles: Fat absorption and atherosclerosis. Science 110, 529–530 (1949).
Becker, G. H., J. Meyer and H. Necheles: Fat absorption in young and old age. Gastroenterology 14, 80–92 (1950).
Becker, G. H., T. W. Rall and M. I. Grossman: Effect of heparin on the distribution of intravenously administered C14-labeled soybean oil emulsion in rats. J. Lab. clin. Med. 45, 786–791 (1955).
Besterman, E. M. M., and J. Evans: Antilipaemic agent without anticoagulant action. Brit. med. J. 2, 310–312 (1957).
Block, W. J., N. W. Barker and F. D. Man: Effect of small dosis heparin in increasing the translutence of plasma during alimentary lipemia. Studies in normal persons and patients having atherosclerosis. Circulation 4, 674–678 (1951).
Borgström, B.: Diskussionsbemerkung zum Vortrag von E. D. Korn: Lipoprotein lipase. In: I. H. Page: Chemistry of lipids as related to atherosclerosis (a symposium, May 1957), pp. 169–188 Springfield, 111.: Ch. C. Thomas 1958.
Boyle, E., J. H. Bragdon and R. K. Brown: Rôle of heparin in in vitro production of alpha lipoproteins in human plasma. Proc. Soc. exp. Biol. (N. Y.) 81, 475–477 (1952).
Boyle, E., J. H. Bragdon and R. K. Brown: Effects of long-term estrogen and heparin administration on serum lipoprotein levels in hypercholesterolemic humans. Circulation 10, 587–588 (1954).
Bragdon, J. H., and R. Havel: a) The heparinlike activity of certain inorganic ions. Science 120, 113–114 (1954).
Bragdon, J. H., and R. Havel: b) Heparinlike activity of polymetaphosphate. Circulation 10, 591 (1954).
Bragdon, J. H., and R. Havel: R. J. Havel and R. S. Gordon: Effects of carbohydrate feeding on serum lipids and lipoproteins in the rat. Amer. J. Physiol. 189, 63–67 (1957).
Bragdon, J. H., and R. Havel: R. J. Havel and R. S. Gordon: On the composition of chyle chylomicrons. J. Lab. clin. Med. 52, 564–570 (1958).
Bragdon, J. H., and R. S. Gordon: Tissue distribution of C14 after the intravenous injection of labeled chylomicrons and unesterified fatty acids in the rat. J. clin. Invest. 37, 574–578 (1958).
Brand, V. Von, H. Drescher U. N. Zöllner: Über die Verwertung parenteral zugeführter Fettemulsionen und ihre Beeinflussung durch Heparin. Nutritio Dieta 1, 161–176 (1959).
Brown, R. K., and D. L. Katjffman: The in vitro production of lipemia clearing factor. Circulation 8, 435 (1953).
Brown, R. K., E. Boyle and C. B. Anfinsen: The enzymatic transformation of lipoproteins. J. biol. Chem. 204, 423–434 (1953).
Brown, W. D.: Protamine, chylomicrons and clot formation. Science 118, 46–47 (1953).
Buck, R. C.: Uptake of radioactive sulfur by vascular tissue. Circulation 10, 595 (1954).
Cantone, A., V. Rulli and B. Rossi: Antilipemic activity of an extract of hog gastric mucosa. Circulât. Res. 7, 291–295 (1959).
Capraro, V., A. Cantone U. A. Cresseri: Über die Anwendung einer resorbierbaren, mit “clearing”-Vermögen versehenen Substanz im normalen Magensaft. Naturwissenschaften 43, 36–37 (1956).
Carlson, L. A., and B. Olhagen: The electrophoretic mobility of chylomicrons in a case of essential hyperlipemia. Scand. J. clin. Lab. Invest. 6, 70–73 (1954).
Carlson, L. A., and L. B. Wadström: Studies on the glycerides during the clearing reaction. Clin. chim. Acta 2, 9–15 (1957).
Chandler, H. L., E. Y. La Wry, K. G. Potee and G. V. Mann: Spontaneous and induced Variations In Serum Lipoproteins. Circulation 8, 723–731 (1953).
Cherkes, A., and R. S. Gordon: The liberation of lipoprotein lipase by heparin from adipose Tissue Incubated In Vitro. J. Lipid Res. 1, 97–101 (1959).
Ciswicka, M., A. Michajlik and M. Sznajderman: Studies on the lipolytic activity of blood Serum In Atherosclerosis. Acta Med. Scand. 101, 391–395 (1958).
Cleland, W. W., and J. M. Iacono: Role of lipoprotein lipase in intravascular clearing of Fat in Human Subjects. Fed. Proc. 16, 383 (1957).
Connor, W. E., and J. W. Eckstein: The removal of lipoprotein lipase from the blood by the Normal and Diseased Liver. J. Clin. Invest. 38, 1746–1755 (1959).
Constantinides, P.: Mast cells and susceptibility to experimental atherosclerosis. Science 117, 505–506 (1953).
Constantinides, P., G. Szasz and F. Harder: Retardation of atheromatosis and adrenal enlargement by heparin in the rabbit. Amer. med. Ass. Arch. Pathol. 55, 36–45 (1953).
Constantinides, P., Y. So and F. R. C. Johnstone: Role of liver and kidney in development of heparin-induced lipemia clearing activity (LCA). Proc. Soc. exp. Biol. (N. Y.) 100, 262–264 (1959).
Day, A. J., G. K. Wilkinson H. R. Gilmore C. J. Schwartz and J. A. Peters: Effect of protamine on alimentary lipemia. Circulation 16, 72–76 (1957).
Day, A. J., C. J. Schwartz and J. A. Peters: Serum lipid responses to heparin and to protamine in rabbits. Austr. J. exp. Biol. med. Sci. 85, 457–465 (1957).
Day, A. J., G. N. Wilkinson and J. A. Peters: Clearing factor inhibitor in human atheroclerosis. Circulation 18, 76–81 (1958).
Dole, V. P.: A relation between non-esterified fatty acids in plasma and the metabolism of glucose. J. clin. Invest. 85, 150–154 (1956).
Dole, V. P.: The Transport Of Non-Esterified Fatty Acids In Plasma. In: I. H. Page: Chemistry of lipids as related to atherosclerosis (a symposium, May 1957), pp. 189–198 Springfield, 111.: Ch. C. Thomas 1958.
Engelberg, H.: Further studies of human circulating plasma heparin levels. Correlation with serum lipids and lipoproteins. Circulation 8, 448 (1953).
Engelberg, H.: a) Studies of normal endogenous lipemia clearing factor. Circulation 10, 590 (1954); b) Correlation of plasma heparin levels and serum low density lipoproteins. Circulation 10, 604–605 (1954).
Engelberg, H.: Human endogenous lipemia clearing activity (studies of lipolysis and effects of inhibitors). J. biol. Chem. 222, 601–610 (1956).
Engelberg, H., and R. Kijhn: Studies of forearm arteriovenous oxygen differences in atherosclerotic patients before and after heparin. Angiology 7, 73–83 (1956).
Engelberg, H., and R. Kijhn: a) In vitro studies of human lipolytic activity before and after oral fat intake. J. Appl. Physiol. 11, 155–160 (1957)
Engelberg, H., and R. Kijhn:b) Human endogenous plasma lipemia clearing and lipolytic activity after tricalcium phosphate adsorption. Proc. Soc. exp. Biol. Med. 95, 394–397 (1957).
Engelberg, H., and D. Rodensky: a) Human endogenous plasma lipemia clearing activity. Observations in 482 individuals. J. Appl. Physiol. 18, 375–380 (1958)
Engelberg, H., and D. Rodensky:b) Quantitative studies of triglyceride lipolysis after heparin administration. Circulat. Res. 6, 266–270 (1958).
Engelberg, H., In vitro studies of the lipolysis of postalimentary lipemia in man. Metabolism 7,172–178 (1958).
Engelberg, H.,a) Studies of fat lipolysis by post-heparin human plasma lipoprotein lipase and by human pancreatic lipase. Circulation 19, 884–890 (1959)
Engelberg, H.B) Effect of epinephrine upon optical density, unesterified fatty acids, lipemia clearing activity and heparin levels. Proc. Soc. exp. Biol. (N. Y.) 100, 492–494 (1959).
Engelberg, H. c) Effect of heparin on serum cholesterol and triglycerides, fecal bile acids and digitonin precipitable sterols. Circulation 20, 976–977 (1959).
Fasoli, A.: Electrophoresis of serum lipoproteins on filter-paper. Acta med. scand. 145, 233–235 (1953).
Fasoli, A., M. D. Glassman, E. B. Magid and P. P. Foa: Serum lipoproteins in experimental diabetes. II) Action of heparin in vivo on lipoproteins of depancreatised dogs. Proc. Soc. exp. Biol. (N. Y.) 86, 298–301 (1954).
Fekete, L. L., W. F. Lever and E. Klein: Inhibition of lipemia clearing activity by human White Blood Cell and Platelet Components. J. Lab. Clin. Med. 52, 680–686 (1958).
Fischer, F. W.: Heparinwirkung auf Lipoide und Lipoproteine. Verh. dtsch. Ges. inn. Med. 68, 625 (1957).
Forbes, A. L.: Incidence of reactions to an intravenous fat emulsion administered at two Different Rates. Metabolism 6, 645–649 (1957).
Foster, A. B., and A. J. Huggard: The chemistry of heparin. Advanc. Carbohyd. Chem. 10, 335–368 (1955), zit. nach Korn (1959C).
Fredrickson, D. S., R. S. Gordon, K. Ono and A. Cherkes: The metabolism of albumin-bound C14-labeled unesterified fatty acids in normal human subjects. J. clin. Invest. 87, 1504–1515 (1958).
French, J. E., D. S. Robinson and H. W. Florey: The effect of the intravenous injection of heparin on the interaction of chyle and plasma in the rat. Quart. J. exp. Physiol. 38, 101–111 (1953).
French, J. E., and P. M. Harris: The role of cholesterol in the interaction of chyle and plasma. Quart. J. exp. Physiol. 40, 320–330 (1955).
French, J. E., B. Morris and D. S. Robinson: Observations in the removel of chylomicra from the blood. Illrd Internat. Confer, on Biochem. Probl. of Lipids. “The blood lipids and the clearing factor”, pp. 323–331 Brüssel 1956.
French, J. E., B. Morris and D. S. Robinson: The tissue distribution and oxydation of 14C-labeled chylomicron fat injected intravenously in rats. J. Physiol. 140, 262–271 (1958).
Gofman, J. W., F. Linbgren, H. Elliot W. Mantz, J. Hewitt, B. Strisower and V. Herring: The role of lipids and lipoproteins in atherosclerosis. Science 111, 166–171, 186 (1950).
Gordon, R. S.: Interaction between oleat and the lipoproteins of human serum. J. clin. Invest. 34, 477 - 484 (1955).
Gordon, R. S., and A. Cherkes: Unesterified fatty acids in human blood plasma. J. clin. Invest. 35, 206–212 (1956).
Gordon, R. S., and H. Gates: Unesterified fatty acids in human blood plasma. II) The transport function of unesterified fatty acids. J. clin. Invest. 36, 810–815 (1957).
Gore, I., and B. Larrey: Functional activity of arterial mucopolysaccharides. Circulation 20, 976 (1959).
Grafnetter, D., U. T. Zemplenyi: Vergleich der Eigenschaften von gewebseigenen lipo- lytischen Enzymen und des Klärungsfaktors bei der Inkubation mit lipämischem Serum. Hoppe-Seylers Z. physiol. Chem. 316, 218–223 (1959).
Graham, D. M., T. P. Lyon, J. W. Gofman, H. B. Jones, A. Yankley, J. Simonton and S. White: Blood lipids and human atherosclerosis. II) The influence of heparin upon lipoprotein metabolism. Circulation 4, 666–673 (1951).
Grossman, M. I., and I. Strub: Effect of heparin on the fate of intravenously administered fat emulsion in rat. Proc. Soc. exp. Biol. (N. Y.) 85, 356–359 (1954).
Grossman, M. I., and L. Palm, G. H. Becker and H. C. Moeller: Effect of lipemia and heparin on free fatty acid content of rat plasma. Proc. Soc. exp. Biol. (N. Y.) 87, 312–315 (1954).
Grossman, M. I., L. Palm, G. H. Becker and H. C. Moeller: The quantitative measurement of heparin-induced lipemia clearing activity of plasma. J. Lab. clin. Med. 48, 445–451 (1954).
Grossman, M. I., J. Stadler, A. Ctjshing and L. Palm: Relation of lipolysis to deturbidification and returbidification in heparin-induced lipemia-clearing phenomenon. Proc. Soc. exp. Biol. (N. Y.) 88, 132–135 (1955).
Hadley, J. L., and H. C. Meng: Pancreas and the production of lipemia clearing factor. Circulation 14, 493 (1956).
Hahn, P. F.: Abolishment of alimentary lipemia following injection of heparin. Science 98, 19–20 (1943).
Hall, D. A.: The reaction between elastase and elastic tissue. I. The substrat. Biochem. J. 59, 459–465 (1955).
Hall, D. A., and J. E. Gardiner: The reaction between elastase and elastic tissue. II. Preparation and properties of the enzyme. Biochem. J. 59, 465–470 (1955).
Hall, D. A.: The complex nature of the enzyme elastase. Arch. Biochem. 67, 366–377 (1957).
Hall, D. A.: The Production of Plasma Clearing Factor In Vitro. Biochem. J. 70, 5P–6P (1958), Dazu: Czerkawski, J. W., and D. A. Hall: The fractionation of elastase preparations. Biochem. J. 70, 6P (1958).
Havel, R. J., and E. Boyle: Production of lipemia clearing factor during anaphylactoid shock. Proc. Soc. exp. Biol. (N. Y.) 85, 468–472 (1954).
Havel, R. J., and. S. Fredrickson: The metabolism of chylomicra. I) The removal of palmitic acid- l-C14-labeled chylomicra from dog plasma. J. clin. Invest. 35, 1025–1032 (1956).
Havel, R. J., and A. Goldfien: The role of the sympathetic nervous system in the metabolism of free fatty acids. J. Lipid. Res. 1, 102–108 (1959).
Herbert, F. A., R. E. Beamish and W. F. Perry: Serum Cholesterin levels in atherosclerotic patients treated with oral anticoagulants. J. Lab. clin. Med. 53, 442–445 (1959).
Herbst, F. S. M., and N. A. Hurley: Effects of heparin on alimentary hyperlipaemia. An electrophoretic study. J. clin. Invest. 33, 907–911 (1954).
Herzstein, J., Ch. I. Wang and D. Adlersberg: a) Effects of heparin on plasma lipids in normal persons, in patients with coronary atherosclerosis, nephrosis and primary hyperlipemia. Circulation 8, 444–445 (1953)
Herzstein, J., Ch. I. Wang and D. Adlersberg:b) Fat loading studies in relation to age. Circulation 8, 450 (1953).
Herzstein, J., Ch. I. Wang and D. Adlersberg: Effect of heparin on plasma lipid partition in man: studies in normal persons and in patients with coronary atherosclerosis, nephrosis and primary hyperlipemia. Ann. intern. Med. 40, 290–306 (1954).
Heymann, H.: Noch unveröffentlicht.
Hollett, C., and H. C. Meng: Purification and characterization of the lipemia clearing factor of postheparin plasma. Biochim. biophys. Acta 20, 421–422 (1956).
Hollett, C., and H. C. Meng: Lipemia clearing factor inhibitor in normal plasma. Fed. Proc. 16, 60–61 (1957).
Holt, K. S.: Idiopathic hyperlipemia. Report of a case studied with radioactive iodine-labeled fat. Arch. Dis. Childh. 32, 142–145 (1957).
Hood, B., and G. Angervall: The relation between inhibition towards clearing, total chol-esterol and the distribution of cholesterol in plasma. Acta med. scand. 158, 13–20 (1957).
Iselin, B., U. W. Schuler: Über die Einwirkung von Heparin auf Lipoprotein-Lipase (Clearing-Factor) aus Gewebe. Helv. physiol. pharmacol. Acta 15, 14–24 (1957).
Jeffries, G. H.: The sites at which plasma clearing activity is produced and destroyed in the rat. Quart. J. exp. Physiol. 39, 261–270 (1954).
Jobst, H.: Die Chylomicronen des Blutes. (Mit einem Beitrag zur Methode der Chylomikronen- zählung im Serum). Klin. Wschr. 33, 746–750 (1955).
Jobst, H., U. G. Schettler: Über die chemische Zusammensetzung der Chylomikronen. Illrd Internat. Conf. on Biochem. Probl. of Lipids, Brüssel 1956: “The blood lipids and the clearing factor”, pp. 136–149.
Keller, R.: Biochemische Eigenschaften und physiologische Bedeutung der Gewebsmast- zellen. Schweiz, med. Wschr. 90, 503–508 (1960) (dort weitere Literatur!).
Kirk, J. E.: Anticoagulant activity of human arterial mucopolysaccharides. Circulation 20, 975–976 (1959).
Klein, E., U. F. H. Franken: Das elektrophoretische Lipoproteinspektrum des Serums nach Heparineinwirkung und bei Leberkrankheiten. Dtsch. med. Wschr. 80, 44–47 (1955).
Klein, E., and F. Lever: Inhibition of lipemia clearing activity by serum of patients with hyperlipemia. Proc. Soc. exp. Biol. (K Y.) 95, 565–567 (1957).
Klein, E., and L. L. Fekete: a) Inhibition of lipemia clearing activity by tissue components. Fed. Proc. 17, 520 (1958).
; b) Inhibition of lipemia clearing activity by tissue extracts. Proc. Soc. exp. Biol. (N. Y.) 98, 658–660 (1958).
Koppel, J. L., L. V. Novak and J. Olvin: Observation on components of the plasma clearing system. Circulation 20, 977–978 (1959).
Korn, E. D.: a) Clearing factor, a heparin-activated lipoprotein lipase. I) Isolation and characterization of the enzym from normal rat heart. J. biol. Chem. 215, 1–14 (1955);
Korn, E. D.: b)Clearing factor, a heparin-activated lipoprotein lipase. II) Substrate specifity and activation of coconut oil. J. biol. Chem. 215, 15–26 (1955).
Korn, E. D., and T. W. Quigley: Studies on lipoprotein lipase of rat heart and adipose tissue. Biochim. biophys. Acta 18, 143–145 (1955).
Korn, E. D., and A. N. Payza: a) Enzymatic degradation of heparin. Biochim. biophys. A.Ta 20, 596–597 (1956)
b) (Payza, A. N., and E. D. Korn:) The degradation of heparin by bacterial enzymes. I. Adaptation and lyophilized cells. J. biol. Chem. 223, 853–858 (1956)
Korn, E. D., and A. N. Payza: c) The degradation of heparin by bacterial enzymes. II. Aceton powder extracts. J. biol. Chem. 223, 859–864 (1956).
Korn, E. D., and A. N. Payza: Inactivation of Lipoprotein Lipase By Heparinase. J. Biol. Chem. 226, 827–832 (1957). [Eine Vorläufige Mitteilung Über Dieses Thema Erschien In: Science 124, 489 (1956)].
Korn, E. D., A. N. Payza, T. W. Quigley: Lipoprotein lipase of chicken adipose tissue. J. biol. Chem. 226, 833–839 (1957).
Korn, E. D., A. N. Payza, T. W. Quigley: Lipoprotein Lipase. In: I. H. Page: Chemistry of lipids as related to atherosclerosis (a symposium, May 1957), pp. 169–188. Springfield, 111.: Ch. C. Thomas 1958.
Korn, E. D:a) The synthesis of heparin by slices of mouse mast cell tumor. J. biol. Chem. 234, 1321 bis 1324 (1959)
Korn, E. D:b) The isolation of heparin from mouse mast cell tumor. J. biol. Chem. 234, 1325–1329 (1959).
Korn, E. D:c) The enzymatic sulfation of heparin. J. biol. Chem. 234, 1647–1650 (1959).
Kraupp, O., S. Sailer U. Ch. Stumpf: Kinetik und Substratabhängigkeit der Trioleinspaltung im Rattenplasma nach Heparinverabreichung. Biochem. Z. 328, 301–308 (1956).
Kunkel, H. A., and R. Trautman: The a-2-lipoproteins of human serum. Correlation of ultracentrifugal and electrophoretic properties. J. clin. Invest. 35, 641–648 (1956).
Kuo, P. T., C. R. Joyner and J. G. Reinhold: Effects of fat ingestion and heparin admini-stration on serum lipids of “normal” hypercholesterolemic, hyperlipemic and atherosclerotic subjects. Amer. J. med. Sci. 232, 613–623 (1956).
De Langen, C. D.: Fat metabolism in hypoxia and its central regulation. Aeromed. Acta (Soesterberg) 3, 97–110 (1954).
Laurell, C. B.: Preliminary data on the composition and certain properties of human chylomicrons. Scand. J. clin. Lab. Invest. 6, 22–24 (1954).
Laurell, S.: The effect of free fatty acids on the migration rates of lipoproteins in paper electrophoresis. Scand. J. clin. Lab. Invest. 7, 28–31 (1955).
Latjrell, S.: Electrophoretic mobility of serum and lymph chylomicrons. Scand. J. clin. Lab. Invest. 11, 97–100 (1959).
Leinwand, I., and D. H. Moore: Serum lipid and protein fractions: IX) Comparisons of ninety-six patients with vascular disease and sixty normal controls (with additional notes on blood donors). Circulation 10, 94–100 (1954).
Lever, W. F., P. A. Smith and N. A. Hurley: Idiopathic hyperlipemia and primary hyper- cholesterolemic xanthomatosis. Ill) Effects of intravenously administered heparin on plasma proteins and lipids. J. invest. Derm. 22, 71–87 (1954).
Lever, W. F., and W. R. Waddell: Idiopathic hyperlipemia and primary hypercholesterolemic xanthomatosis. VII) Effects of intravenously administered fat on the serum lipids. J. invest. Derm. 25, 233–248 (1955).
Lever, W. F., and E. Klein: a) The inhibition of lipemia-clearing by hyperlipemic serum. J. invest. Derm. 29, 465–469 (1957)
Lever, W. F., and E. Klein:b) Untersuchungen uber die Pathogenese der idiopathischen Hyperlipaemie. Dermatologica (Basel) 115, 579–586 (1957).
Lever, W. F., and E. Klein: a) Primary hypercholesterolemia and idiopathic hyperlipemia; clinical, biochemical and therapeutical aspects. Sth. med. J. 53, 454–464 (1960).
Levine, L., D. L. Kauffman and R. K. Brown: The antigenic similarity of human low density lipoproteins. J. exp. Med. 102, 105–118 (1955).
Levy, S. W.: Heparin and blood lipids. Rev. canad. Biol. 17, 1–61 (1958).
Lewis, K. F., A. Allen and S. Weinhouse: Substrate competition in glucose and palmitate oxydation in the intact rat. Arch. Biochem. 85, 499–511 (1959)
Lindgren, F. T., N. K. Freeman Andd. M. Graham: In vitro lipoprotein transformations. Circulation 6, 474–475 (1952).
Lindgren, F. T., and J. W. Gofman: The rôle of lipoproteins in coronary disease. Bull, schweiz. Akad. med. Wiss. 13, 152–178 (1957).
Logemann, W.: Zur Klârwirkung des Heparins. Naturwissenschaften 44, 423–424 (1957).
Matras, A.: Hyperlipaemische Xanthomatosen und ihre Behandlung mit Heparin. Arch, klin. exp. Derm. 203, 503–518 (1956).
Meng, H. C., and W. S. Davis: Effects of heparin on the development of atherosclerosis and of fatty liver in cholesterol-fed rabbits. Circulation 10, 590–591 (1954).
Meng, H. C., C. Hollett and W. E. Cole: Some factors affecting the clearing of neutral fat emulsion by postheparin plasma. Amer. J. Physiol. 179, 314–318 (1954).
Meng, H. C., W. J. Mcganity: Effects of pregnancy on heparin-induced lipemia clearing factor and serum lipids. Fed. Proc. 17, 110 (1958).
Michajlik, A., and J. H. Bragdon: Effects of carbohydrates on fat absorption. Circulation 20, 964 (1959).
Michajlik, A., and J. H. Bragdon: Effects of intravenous heparin on oxydation of fat. J. Lipid Res. 1, 164–166 (1960).
Middleton, E.: Immunochemical relationship of the protein moieties of human lipo-protein and chylomicrons. Circulation 10, 596 (1954).
Mora, R., P. Rebeyrotte Et J. Polonovski: Influence des substances tensioactives sur la mobilité électrophorétique des lipoprotéides plasmatiques. Bull. Soc. Chim. biol. (Paris) 37, 957–968 (1955).
Morris, B., and F. C. Cottrtice: The origin of chylomicrons in the cervical and hepatic lymph. Quart. J. exp. Physiol. 41, 341–348 (1955).
Morris, B., and F. C. Cottrtice: a) The Hepatic and Intestinal Contributions To The Thoracic Duct Lymph. Quart. J. Exp. Physiol. 41, 318–325 (1956);
Morris, B., and F. C. Cottrtice: b) The Exchange Of Lipids Between The Circulating Plasma and The Hepatic Lymph. Illrd Internat. Conf. On Biochem. Probl. Of Lipids. Cottrtice: b) The Exchange Of Lipids Between The Circulating Plasma and The Hepatic Lymph. Illrd Internat. Conf. On Biochem. Probl. Of Lipids: “The blood lipids and the clearing factor”; pp. 311–322 Briissel 1956.
Morris, B., and J. E. French: The uptake and metabolism of 14C-labeled chylomicron fat by the isolated perfused liver of the rat. Quart. J. exp. Physiol. 43, 180–188 (1958).
Nichols, A. V., N. K. Freeman, B. Shore and L. Rubin: The interaction of “heparin active factor” and lipoproteins. Circulation 6, 457–458 (1952).
Nikkila, E. A., and S. Majanen: The blood heparinoid substances in human atherosclerosis. Scand. J. clin. Lab. Invest. 4, 204–210 (1952).
Nikkila, E. A., and S. Majanen: Studies on the lipid-protein relationships in normal and pathological sera and the effect of heparin on serum lipoproteins. Scand. J. clin. Lab. Invest. 5, Suppl. 8 (1953).
Nikkila, E. A., and R. Grasbeck: Heparin in lipoid nephrosis. Observations on the effects on edema, proteinuria, serum proteins, lipids and lipoproteins. Acta med. scand. 150, 39–46 (1954).
Nikkila, E. A., and E. Haahti: On the mechanism of the heparin-induced lipemia clearing reaction. Acta chem. scand. 8, 363–364 (1954).
Nikkila, E. A., and R. Pesola: Purification of clearing factor from postheparin plasma. Acta chem. scand. 10, 144–145 (1956).
Nikkilä, A. E. and T. Niemi: Effect of age on the lipemia clearing activity of serum after administration of heparin to human subjects. J. Geront. 12, 44–47 ) 1957 ).
Oliver, M. F., and G. S. Boyd: The clearing by heparin of alimentary lipemia in coronary artery disease. Clin. Sci. 12, 293–298 (1953).
Overbeck, G. A., and J. Van Der Vies: Clearing factor and lipase. Biochem. J. 60, 665–670 (1955).
Pilgeram, L. O., and L. C. Rose: Partial characterization of a lipemia clearing defect in atherosclerosis. Circulation 14, 502 (1956).
Pollak, O. J.: Aortic mast cells in man and rabbit. Circulation 14, 503 (1956).
Le Quire, V. S., L. M. Worley and M. E. Gray: The effects of hypoxia upon the lipemia- clearing response to intravenous heparin. J. Lab. clin. Med. 49, 869–876 (1957).
Reiser, R., M. C. Williams and M. F. Sorrels: The transport and dynamic state of exogenous glycerol- and palmitic-acid-labeled tripalmitin. J. Lipid. Res. 1, 241–247 (1960).
Robinson, D. S., and J. E. French: The role of albumen in the interaction of chyle and plasma in the rat. Quart. J. exp. Physiol. 38, 233–239 (1953).
Robinson, D. S., G. H. Jeffries and J. E. French: Studies on the interaction of chyle and plasma in the rat. Quart. J. exp. Physiol. 39, 165–176 (1954).
Robinson, D. S., and J. C. F. Poole: Further studies on the interaction of chyle and plasma in the rat. Quart. J. exp. Physiol. 40, 297–308 (1955).
Robinson, D. S., P. M. Harris, J. C. F. Poole and G. H. Jeffries: The effect of a fat meal on the concentration of free fatty acids in human plasma. Biochem. J. 60, 37 P (1955).
Robinson, D. S., P. M. Harris, J. C. F. Poole and G. H. Jeffries: Further studies on the lipolytic system induced in plasma by heparin injection. Quart. J. exp. Physiol. 41, 195–204 (1956).
Robinson, D. S., P. M. Harris and J. E. French: Changes in the solubility of cholesterol during the interaction of chyle and plasma. Quart. J. exp. Physiol. 41, 309–317 (1956).
Robinson, D. S., P. M. Harris and J. E. French: The production of lipolytic activity in the circulation of the hind limb in response to heparin. Quart. J. exp. Physiol. 44, 80–90 (1959).
Robinson, D. S., and C. R. Ricketts: The production of lipolytic activity in rat plasma after the intravenous injection of dextran sulphate. Biochem. J. 71, 286–292 (1959).
Robinson, D. S., and C. R. Ricketts: The heparin clearing reaction. Amer. J. clin. Nutr. 8, 7–20 (1960).
Rodbell, M., and D. S. Fredrickson: The nature of the proteins associated with dog an human chylomicrons. J. biol. Chem. 234, 562–566 (1959).
Rodbell, M., D. S. Fredrickson and K. Ono: Metabolism of chylomicron proteins in the dog. J. biol. Chem. 234, 567–571 (1959).
Rosenberg, I. N.: Serum lipid studies by electrophoresis on paper. Proc. Soc. exp. Biol. (N. Y.) 80, 751–756 (1952).
Rosenman, R. H., M. Friedman, M. K. Byers and M. K. Smith: The causal role of plasma albumin deficiency in experimental nephrotic hyperlipemia and hypercholesteremia. J. clin. Invest. 35, 522–532 (1956).
Rubin, L., and F. Aladjem: Serum lipoprotein changes during fasting in man. Amer. J. Physiol. 178, 263–266 (1954).
Saxl, H.: The physiological significance of the reaction between elastin and elastomucase in relation to the production of “clearing factor”. Gerontologia (Basel) 1, 142–163 (1957).
Schettler, G.: Arteriosklerose. Stuttgart: Georg Thieme 1961.
Schettler, G., U. H. Jobst: Die Bedeutung alimentärer Fettbelastungen für die Diagnose der Arteriosklerose. Dtsch. med. Wschr. 80, 1077–1089 (1955).
Schettler, G., M. Eggstein, F. Dietrich U. H. Jobst: Zur Bestimmung der Serumlipoproteide mit der Zonenelektrophorese im Stärkemedium. Klin. Wschr. 35, 268–275 (1957).
Schettler, G., U. H. Jobst: Die essentielle Hyperlipämie. Dtsch. med. Wschr. 83, 1–12, 25 (1858).
Schmid, K.: Electrophoresis of human serum albumin at PH 4,0.1. A systematic study on the effect of organic acids and alcohols upon the electrophoretic behavior of albumin. J. biol. Chem. 234, 3163–3168 (1959).
Schubert, M., and D. Hamerman: Metachromasia; chemical theory and histochemical use. J. Histoehem. Cytochem. 4, 159–189 (1956).
Schug, E.: Untersuchungen über die Lipoproteide des Serums unter Verwendung der prä- parativen Zonenelektrophorese im Stärkemedium. Inaug. Diss. (Marburg 1956 ).
Schuler, W., G. Müller U. F. Maier: Lipämieklärung in vivo ohne Clearing-Factor. Schweiz, med. Wschr. 87, 787–790 (1957).
Schuler, W., U. G. F. Springer: Experimentelle Antilipaemiewirkung von Fucoidin. Natur-wissenschaften 44, 265 (1957).
Seifter, J., and D. H. Baeder: Lipemia clearing by hyaluronidase, hyaluronate, and desoxycorticosterone, and its inhibition by cortisone, stress and nephrosis. Proc. Soc. exp. Biol. (N. Y.) 86, 709–713 (1954).
Seifter, J., and D. H. Baeder: a) Occurrence in plasma of an extractable lipid mobilizer (LM). Proc. Soc. exp. Biol. (N. Y.) 91, 42–45 (1956);
Seifter, J., and D. H. Baeder: b) Relation of endocrines and clearing factor inhibitors to hyperlipemia in fasted animals. Proc. Soc. exp. Biol. (N. Y.) 93, 63–67 (1956).
Seifter, J., and D. H. Baeder: a) Lipid mobilizer (LM) from posterior pituitary of hogs. Proc. Soc. exp. Biol. (N. Y.) 95, 318–320 (1957);
Seifter, J., and D. H. Baeder: b) Lipid mobilization by a crystalline peptide isolated from plasma of horses administered cortisone. Proc. Soc. exp. Biol. (N. Y.) 95, 469–471 (1957); c) Role of liver on consequences of lipid mobilization. Proc. Soc. exp. Biol. (N. Y.) 95, 747–750 (1957).
Shafrir, E., K. E. Sussman and D. Steinberg: The nature of the epinephrine-induced hyperlipidemia in dogs and its modification by glucose. J. Lipid Res. 1, 109–117 (1959).
Shapiro, B., I. Chowers and G. Rose: Fatty acid uptake and esterification in adipose tissue. Biochim. biophys. Acta 28, 115–120 (1957).
Shore, B., A. V. Nichols and N. K. Freeman: Evidence for lipolytic action by human plasma obtained after intravenous administration of heparin. Proc. Soc. exp. Biol. (N. Y.) 83, 216–220 (1953).
Shore, B., A. V. Nichols and N. K. Freeman: Heparin-activated enzym system of human plasma. Proc. Soc. exp. Biol. (N. Y.) 88, 73–75 (1955).
Shore, B., A. V. Nichols and N. K. Freeman: C- and N-terminal amino acids of human serum lipoproteins. Fed. Proc. 16, 247–248 (1957).
Shoulders, H. H.. H. C. Meng and S. Tuggle: Effects of heparin on body temperature and plasma lipids following intravenous administration of fat emulsion in man. J. Lab. clin. Med. 52, 559–563 (1958).
Spitzer, J. J.: Haemorrhagic lipemia and the production of clearing factor in rabbits. Cir-culation 10, 611–612 (1954).
Spitzer, J. J., and J. A. Spitzer: Haemorrhagic lipemia: a derangement of fat metabolism. J. Lab. clin. Med. 46, 461–470 (1955).
Spitzer, J. J., and J. A. Spitzer: Heparin and Lipid Transport. Illrd Internat. Conf. Biochem. Probl. Of Lipids: “The blood lipids and the clearing factor”; pp. 243–254 Brüssel 1956.
Spitzer, J. A., and J. J. Spitzer: Effect of liver on lipolysis by normal and postheparin sera in the rat. Amer. J. Physiol. 185, 18–22 (1956).
Steiger, W. A., C. J. D. Zarafonetis, G. M. Miller, J. Seifter and D. H. Baeder: Preliminary report on the effects of a plasma lipid mobilizing factor in man. Amer. J. med. Sci. 282, 605–612 (1956).
Stork, A., U. L. Kuöerovä: Die Klärungsfähigkeit des Blutplasmas nach intravenöser Heparininjektion in Beziehung zur Atherosklerose. Z. Ges. inn. Med. 11, 276–281 (1956).
Stork, A., U. L. Kuöerovä: Die Klärungsfähigkeit des Blutplasmas und Veränderungen des Plasmacholesterin-spiegels nach intravenöser Heparininjektion bei Diabetikern und Atherosklerosekranken. Dtsch. med. Wschr. 82, 1410–1413 (1957).
Studer, A., F. Koller, P. Kaegi, K. Vogler,W. Oberhänsli Und M. Kefler: Eigenschaften eines neuen Heparinoids im Tierversuch und am Menschen. Bull. Schweiz. Akad. med. Wiss. 13, 239–261 (1957).
Stuhlfatjth, K., U. N. Zöllner: Der Einfluß von Fruktose auf den Gehalt des Serums an unveresterten Fettsäuren. KLIN. Wschr. 37, 1162–1165 (1959).
Swahn, B.: Studies on blood lipids. III) Electrophoretic mobility of “chylomicrons”. Scand. J. clin. Lab. Invest. 5, Suppl. 9, pp. 80–110 (1953).
Swank, R. L., and V. Wilmot: Chylomicra: Their composition and their fate after intra-venous injection of small amounts of heparin. Amer. J. Physiol. 167, 403–412 (1951).
Thomas, W. A., and J. H. Olwin: Variation in protamine titration results in the blood of atherosclerotic patients. Angiology 9, 279–282 (1958).
Volk, B. W., S. Losner and A. Einhorn: Effect of experimentally induced fever on alimen-tary lipemia. Proc. Soc. exp. Biol. (N. Y.) 98, 31–33 (1958).
Wadström, L. B.: Lipolytic effect of the injection of adrenaline on fat depots. Nature (Lond.)179, 259–260 (1957).
Wagner, A.: The effect of phosphatide on the disappearance of free cholesterol from incubated sera normal and heparinized. J. Lab. clin. Med. 44, 945 (1954).
Weld, C. B.: Alimentary lipemia and heparin. Canad. med. Ass. J. 51, 578 (1944).
Wenke, M., J. Wenkeovä, E. Mühlbachova, D. Skrobal U. M. Andelova: Zum Mechanismus der Protaminhyperlipaemie bei Ratten. Z. Ges. inn. Med. 13, 104–108 (1958).
Wenke, M., U. D. Skrobal: Protaminhyperlipaemie und Metabolismus von Glyceriden. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmak. 236, 79–81 (1959).
Woldow, A., J. E. Chapman and J. M. Evans: Fat tolerance in subjects with atherosclerosis; heparin effects upon lipemia, lipoproteins and gamma globulin. Amer. Heart. J. 47, 568 bis 579 (1954).
Yasugi, T., J. W. Gofman, O. De Lalla, A. R. Tamplin and K. Oshima: Relationship of blood heparin levels to serum lipoproteins and cholesterol levels in fasting subjects. Proc. Soc. exp. Biol. (N. Y.) 98, 46–49 (1958).
Zarafonetis, C. J. D., G. M. Miller, J. Seifter, D. H. Baeder, R. M. Myerson and W. A. Steiger: Metabolic studies in patients receiving lipid mobilizer hormone. Amer. J. med. Sci. 234, 493–504 (1957).
Zarafonetis, C. J. D., G. M. Miller, J. Seifter, D. H. Baeder, R. M. Myerson and W. A. Steiger: Effect of prefeeding on the acute response to lipid mobilizer hormone in man. Amer. J. Med. Sci. 235, 410–419 (1958).
Zemplényi, T., Z. Lodja and D. Grafnetter: Relationship of lipolytic and esterolytic activity of the aorta to susceptibility to experimental atherosclerosis. Circulat. Res. 7, 286–290 (1959).
Zisko, A. P.: The effect of heparin on development of experimentally induced atherosclerosis. Bjull. eksp. Biol. Med. 45, Heft 5, 29–33 (1958); zit. nach einem Ref. in: Kongrzentrbl. inn. Med. 196, 226 (1959).
Zöllner, N., E. Rothemund U. W. Seitz: Ein antilipaemisches, nicht gerinnungshemmendes Abbauprodukt Des Heparins. Klin. Wschr. 32, 1096–1097 (1954).
Zöllner, N., U. H. D. Frings: Über den Einfluß von Heparin auf die Verwertung von Nahrungsfett. Z. ges. exp. Med. 127, 578–586 (1956).
Zöllner, N., U. E. Rothemund: Über Die Bildung Des Lipaemieklärungsfaktors In Vitro. Versuche zur Quantitativen Bestimmung. Hoppe Seylers Z. Physiol. Chem. 307, 112–123 (1957).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1961 Springer-Verlag OHG. Berlin · Göttingen · Heidelberg
About this paper
Cite this paper
Schöll, H., Schettler, G. (1961). Die Lipoproteidlipase und ihre klinische Bedeutung. In: Heilmeyer, L., Schoen, R., De Rudder, B. (eds) Ergebnisse der Inneren Medizin und Kinderheilkunde. Ergebnisse der Inneren Medizin und Kinderheilkunde , vol 16. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-94808-4_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-94808-4_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-94809-1
Online ISBN: 978-3-642-94808-4
eBook Packages: Springer Book Archive